Open AccessStatin adjunctive therapy shortens the duration of TB treatment in mice
Author(s) -
Noton K. Dutta,
Natalie Bruiners,
Michael L. Pinn,
Matthew Zimmerman,
Brendan Prideaux,
Véronique Dartois,
Maria Laura Gennaro,
Petros C. Karakousis
Publication year - 2016
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkw014
Subject(s) - simvastatin , medicine , repurposing , regimen , pharmacology , statin , drug , drug repositioning , pharmacotherapy , adjunctive treatment , ecology , biology
The repurposing of existing agents may accelerate TB drug development. Recently, we reported that the lipid-lowering drug simvastatin, when added to the first-line antitubercular regimen, reduces the lung bacillary burden in chronically infected mice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom